## Natasa Toplak

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4643791/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	EULAR/PRES recommendations for vaccination of paediatric patients with autoimmune inflammatory rheumatic diseases: update 2021. Annals of the Rheumatic Diseases, 2023, 82, 35-47.	0.9	23
2	Safety and immunogenicity of BNT162b2 mRNA COVID-19 vaccine in adolescents with rheumatic diseases treated with immunomodulatory medications. Rheumatology, 2022, 61, 4263-4272.	1.9	29
3	Consensus-based recommendations for the management of juvenile systemic sclerosis. Rheumatology, 2021, 60, 1651-1658.	1.9	20
4	Childhood-onset of primary Sjögren's syndrome: phenotypic characterization at diagnosis of 158 children. Rheumatology, 2021, 60, 4558-4567.	1.9	24
5	ls Anti-NXP2 Autoantibody a Risk Factor for Calcinosis and Poor Outcome in Juvenile Dermatomyositis Patients? Case Series. Frontiers in Pediatrics, 2021, 9, 810785.	1.9	4
6	PIK3AP1 and SPON2 Genes Are Differentially Methylated in Patients With Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) Syndrome. Frontiers in Immunology, 2020, 11, 1322.	4.8	7
7	Live attenuated MMR/V booster vaccines in children with rheumatic diseases on immunosuppressive therapy are safe: Multicenter, retrospective data collection. Vaccine, 2020, 38, 2198-2201.	3.8	41
8	Vaccination for Children on Biologics. Current Rheumatology Reports, 2020, 22, 26.	4.7	14
9	Vaccination coverage in children with rheumatic diseases. Clinical and Experimental Rheumatology, 2020, 38, 164-170.	0.8	8
10	Chronic non-bacterial osteomyelitis: a retrospective international study on clinical manifestations and response to treatment. Clinical and Experimental Rheumatology, 2020, 38, 1255-1262.	0.8	3
11	Classification criteria for autoinflammatory recurrent fevers. Annals of the Rheumatic Diseases, 2019, 78, 1025-1032.	0.9	300
12	Consensus-based recommendations for the management of juvenile localised scleroderma. Annals of the Rheumatic Diseases, 2019, 78, 1019-1024.	0.9	76
13	ldiopathic inflammatory myopathies: state of the art on clinical practice guidelines. RMD Open, 2019, 4, e000784.	3.8	19
14	An international delphi survey for the definition of the variables for the development of new classification criteria for periodic fever aphtous stomatitis pharingitis cervical adenitis (PFAPA). Pediatric Rheumatology, 2018, 16, 27.	2.1	21
15	The Slovene version of the Juvenile Arthritis Multidimensional Assessment Report (JAMAR). Rheumatology International, 2018, 38, 363-369.	3.0	0
16	Sjögren's syndrome: state of the art on clinical practice guidelines. RMD Open, 2018, 4, e000789.	3.8	34
17	The role of IL-1 inhibition in systemic juvenile idiopathic arthritis: current status and future perspectives. Drug Design, Development and Therapy, 2018, Volume 12, 1633-1643.	4.3	39
18	Functional Complement Analysis Can Predict Genetic Testing Results and Long-Term Outcome in Patients With Complement Deficiencies. Frontiers in Immunology, 2018, 9, 500.	4.8	6

NATASA TOPLAK

#	Article	IF	CITATIONS
19	Relationship Between Polymorphisms in Methotrexate Pathway Genes and Outcome of Methotrexate Treatment in a Cohort of 119 Patients with Juvenile Idiopathic Arthritis. Journal of Rheumatology, 2017, 44, 1216-1223.	2.0	18
20	Clinical and MRI outcome of cervical spine lesions in children with juvenile idiopathic arthritis treated with anti-TNFI± drugs early in disease course. Pediatric Rheumatology, 2017, 15, 38.	2.1	14
21	Acute rheumatic fever outbreak in southern central European country. European Journal of Pediatrics, 2017, 176, 23-29.	2.7	10
22	Management of Juvenile Idiopathic Arthritis: A Clinical Guide. Paediatric Drugs, 2016, 18, 397-412.	3.1	34
23	Autoimmune and Inflammatory Manifestations in 247 Patients with Primary Immunodeficiency—a Report from the Slovenian National Registry. Journal of Clinical Immunology, 2016, 36, 764-773.	3.8	22
24	Distribution of MEFV gene mutations and R202Q polymorphism in the Serbian population and their influence on oxidative stress and clinical manifestations of inflammation. Pediatric Rheumatology, 2016, 14, 39.	2.1	10
25	Raynaud's syndrome in children: systematic review and development of recommendations for assessment and monitoring. Clinical and Experimental Rheumatology, 2016, 34 Suppl 100, 200-206.	0.8	10
26	Autoimmune hepatitis as a presenting manifestation of mixed connective tissue disease in a child Case report and review of the literature. Pediatric Rheumatology, 2015, 13, 47.	2.1	10
27	IgA-dominant acute poststreptococcal glomerulonephritis with concomitant rheumatic fever successfully treated with steroids: a case report. Croatian Medical Journal, 2015, 56, 567-572.	0.7	9
28	Clinical Features and Genetic Background of the Periodic Fever Syndrome with Aphthous Stomatitis, Pharyngitis, and Adenitis: A Single Center Longitudinal Study of 81 Patients. Mediators of Inflammation, 2015, 2015, 1-8.	3.0	55
29	The carrier rate and spectrum of MEFV gene mutations in central and southeastern European populations. Clinical and Experimental Rheumatology, 2015, 33, S19-23.	0.8	2
30	An International registry on Autoinflammatory diseases: the Eurofever experience. Annals of the Rheumatic Diseases, 2012, 71, 1177-1182.	0.9	158
31	Periodic fever syndromes in Eastern and Central European countries: results of a pediatric multinational survey. Pediatric Rheumatology, 2010, 8, 29.	2.1	27
32	Influenza and Autoimmunity. Annals of the New York Academy of Sciences, 2009, 1173, 619-626.	3.8	38
33	Antiphospholipid antibodies in response to infection. Current Rheumatology Reports, 2007, 9, 212-218.	4.7	78